Company Overview - ANIXA BIOSCIENCES INC currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable market performance [4] Price Performance - Over the past week, ANIX shares increased by 1.2%, while the Zacks Medical - Biomedical and Genetics industry declined by 2.54% [6] - In the last month, ANIX shares rose by 30.32%, significantly outperforming the industry's 1.71% [6] - Over the past quarter, ANIX shares have risen by 19.93%, and over the last year, they are up 39.66%, compared to the S&P 500's increases of 5.86% and 12.83%, respectively [7] Trading Volume - ANIX's average 20-day trading volume is 245,662 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for ANIX has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$0.41 to -$0.38 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong price performance, positive earnings outlook, and high Momentum Style Score, ANIXA BIOSCIENCES INC is positioned as a promising investment opportunity [12]

Core Insights - Anixa Biosciences has initiated dosing for the first patient in the fourth dosage cohort of its Phase 1 clinical trial for CAR-T therapy targeting recurrent ovarian cancer, marking a significant advancement in the study [1][2] - The fourth cohort will receive a dose of three million CAR-positive cells per kilogram, which is thirty times higher than the initial cohort dose, indicating a strategic escalation in dosage to assess safety and efficacy [2][4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a specific emphasis on ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [4] - The company's CAR-T technology targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells and certain cancer cells, positioning it uniquely in the oncology landscape [3][4] - Anixa's business model involves partnerships with leading research institutions, allowing for the exploration of emerging technologies in cancer treatment [4]

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

Core Viewpoint - ANIXA BIOSCIENCES INC is identified as a promising momentum stock with a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating potential for near-term price increases [3][12]. Momentum Style Score Analysis - The Momentum Style Score incorporates price changes and earnings estimate revisions, which are critical for assessing stock performance [2][9]. - ANIX's shares have increased by 7.39% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 5.43% during the same period [6]. - Over the past month, ANIX's price change is 27.82%, significantly higher than the industry's 6.65% [6]. Long-Term Performance Metrics - In the last quarter, ANIX shares rose by 12.21%, and over the past year, they increased by 27.34%, while the S&P 500 only moved 4.46% and 13.71%, respectively [7]. - The average 20-day trading volume for ANIX is 154,337 shares, indicating a bullish trend when combined with rising stock prices [8]. Earnings Outlook - In the past two months, one earnings estimate for ANIX has been revised upward, while none have been lowered, leading to an increase in the consensus estimate from -$0.41 to -$0.38 [10]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions, suggesting positive sentiment around future earnings [10].

SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer tr ...

SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congr ...

Core Viewpoint - Anixa Biosciences Inc (ANIX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance Indicators - Anixa Biosciences is projected to earn -$0.38 per share for the fiscal year ending October 2025, reflecting a year-over-year change of 2.6% [7]. - Over the past three months, the Zacks Consensus Estimate for Anixa has increased by 7.3%, indicating a positive revision trend [7]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6][8]. - Anixa's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Company Overview - ANIXA BIOSCIENCES INC is part of the Medical group, which consists of 999 companies and is currently ranked 4 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 503 companies and is ranked 78 in the Zacks Industry Rank [5] Performance Metrics - Year-to-date, ANIXA BIOSCIENCES INC has increased by approximately 20.3%, outperforming the average loss of 4.4% in the Medical group [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has risen by 7.3% over the past quarter, indicating improved analyst sentiment and earnings outlook [3] Comparative Analysis - Another outperforming stock in the Medical sector is Cellectar Biosciences, Inc., which has returned 54.4% year-to-date [4] - Cellectar Biosciences, Inc. belongs to the Medical - Products industry, which has a lower ranking (134) and has increased by 5.2% this year [6]

Core Insights - Anixa Biosciences, Inc. is advancing a breast cancer vaccine that aims to train the immune system to identify and eliminate cancerous cells before they develop into invasive tumors [2][3] - The vaccine specifically targets α-lactalbumin, a protein expressed in the breast during lactation, which is also found in malignant breast cancer cells [2] - The company has completed enrollment in the Phase 1 clinical trial for the vaccine and is optimistic about its potential impact on breast cancer treatment and prevention [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a unique CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by targeting the natural ligand of the FSHR receptor on tumor cells [4] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers such as lung, colon, and prostate [4]

Revenue - No revenue was generated during the three-month and six-month periods ended April 30, 2025 and 2024[84][92] Expenses - Research and development expenses decreased by approximately $324,000 to approximately $1,322,000 in the three months ended April 30, 2025, compared to approximately $1,646,000 in the same period of 2024[87] - General and administrative expenses decreased by approximately $140,000 to approximately $1,681,000 in the three months ended April 30, 2025, from approximately $1,821,000 in the same period of 2024[88] - Research and development expenses for cancer vaccines and CAR-T therapeutics were approximately $1,873,000 and $1,001,000, respectively, during the six months ended April 30, 2025[94] - General and administrative expenses decreased by approximately $566,000 to approximately $3,515,000 in the six months ended April 30, 2025, from approximately $4,081,000 in the same period of 2024[96] Income - Interest income decreased by approximately $96,000 to approximately $190,000 in the three months ended April 30, 2025, from approximately $287,000 in the same period of 2024[89] - Interest income decreased by approximately $243,000 to approximately $363,000 in the six months ended April 30, 2025, from approximately $606,000 in the same period of 2024[97] Assets and Cash Flow - Total current assets decreased by approximately $4,596,000 to approximately $16,766,000 at April 30, 2025, compared to approximately $21,362,000 at October 31, 2024[100] - Cash used in operating activities was approximately $4,407,000 during the six months ended April 30, 2025[101] Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $24,000 to approximately $52,000 in the six months ended April 30, 2025, from approximately $76,000 in the same period of 2024[98] Internal Controls - There was no change in internal control over financial reporting during the three months ended April 30, 2025, that materially affected internal control[117] - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures are effective as of the end of the reporting period[116] Compensation Allocation - The company allocates certain internal compensation costs to research and development expenses based on management's estimates of employee time and effort[113]